Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 23 clinical trials
Mocetinostat With Vinorelbine in Children, Adolescents & Young Adults With Refractory and/or Recurrent Rhabdomyosarcoma

This phase I trial studies the side effects and best dose of mocetinostat when given together with vinorelbine to see how well it works in treating children, adolescents, and young adults with

metastasis
cancer
neutrophil count
shortening fraction
vinorelbine
  • 0 views
  • 27 May, 2022
  • 1 location
A Phase II, Single-arm, Two-cohorts, Open-label, Single Center Study of Surufatinib or Surufatinib Combined With Vinorelbine as Third-line and Posterior Line Treatment in Patients With Non-Small Cell Lung Cancer

A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined with Vinorelbine as third-line and posterior line treatment in patients with NSCLC

  • 0 views
  • 18 Sep, 2022
  • 1 location
GVD±R Regimen for ASCT-eligible Patients With Refractory/Relapsed DLBCL

The purpose of this multi-center,single arm,phase clinical trail is to determine the safety and efficacy of GVDR (gemcitabine, oral vinorelbine and doxorubicin liposome, with or without

b-cell lymphoma
rituximab
gemcitabine
cell transplantation
doxorubicin
  • 13 views
  • 15 Feb, 2022
  • 1 location
Using a Modified ALCL99 Regimen for Chinese Children With Newly Diagnosed High-risk Anapestic Large Cell Lymphoma

A prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.

  • 0 views
  • 23 Sep, 2022
  • 1 location
A Phase I Trial of the Hypoxia Modifier Atovaquone in Combination With Radical Concurrent Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer (ARCADIAN)

This is a phase I, single arm, open-label trial that will utilise a Time To Event Continual Reassessment Method (TiTE-CRM) to determine the maximum tolerated dose (MTD) of atovaquone in combination with concurrent CRT in NSCLC. Twenty evaluable participants will be recruited at three centres.

  • 0 views
  • 23 Sep, 2022
  • 2 locations
Study of Docetaxel or Vinorelbine Plus Cisplatin in Neoadjuvant Chemoradiotherapy for Esophageal Cancer

The primary objective is to compare docetaxel plus cisplatin (DP) versus vinorelbine plus cisplatin (NP) in neoadjuvant chemoradiotherapy, in terms of the overall survival and toxicity in

cancer
docetaxel
blood count
esophagus cancer
vinorelbine
  • 15 views
  • 24 Jan, 2021
  • 1 location
A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

chemotherapy (eribulin, capecitabine, vinorelbine, or gemcitabine) in participants with inoperable or metastatic HR-positive, HER2- negative breast cancer who have been treated with one or two prior lines of

estrogen
erbb2
capecitabine
HER2
vinorelbine
  • 0 views
  • 14 Jul, 2022
  • 94 locations
A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer (innovaTV 301)

vedotin. Participants in the other group will get one of five different chemotherapy drugs (topotecan, vinorelbine, gemcitabine, pemetrexed, or irinotecan). Participants and their doctors will know which

pemetrexed
treatment regimen
immunomodulator
bevacizumab
carboplatin
  • 3 views
  • 23 Sep, 2022
  • 97 locations
Cipterbin Combined With Vinorelbine in the Treatment of HER2-positive MBC

To compare pharmacokinetics Index of Cipterbin combined with Vinorelbine Injection every week or every three weeks in the treatment of patients with HER2-positive metastatic breast cancer

  • 0 views
  • 28 Nov, 2021
  • 1 location
Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

This is a proof-of-concept study to define efficacy of vinorelbine, cisplatin, disulfiram and copper in CTC_EMT positive refractory metastatic hormone receptor positive, HER2 negative breast

paclitaxel
kidney function tests
bone metastases
vinorelbine
alopecia
  • 37 views
  • 26 Feb, 2022
  • 1 location